$RFL News

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint

Rafael Holdings stock tumbles 25% as drug trial misses goal

Why Is Rafael Stock Falling Wednesday?

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript

Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Q3 EPS $(0.08) Up From $(0.19) YoY, Sales $179.000K Down From $362.000K YoY

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Rafael Holdings Announces Last Patient Completed Final 96-Week Study Visit In Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C; Topline Results Expected In H2 Of Calendar 2026

Rafael Holdings Insider Ups Holding By 1,810% During Year

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Rafael Holdings' Cyclo Therapeutics Enters Into Exclusive Licensing Agreement With MIT For Small Molecules To Improve Myelination In Apoe4 Positive Alzheimer's Disease

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Q2 EPS $(0.13) Up From $(0.19) YoY, Sales $211.000K Up From $77.000K YoY

Evaluating Alzheimer's Disease Treatments

12 Health Care Stocks Moving In Monday's Intraday Session

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results